Hussein Assi, MD, MS

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Assi is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the section of Hematology/Oncology at Boston Medical Center (BMC). He graduated from medical school at the American University of Beirut in Lebanon and completed his residency in Internal Medicine at Albany Medical Center in Albany, NY. He further completed his training in Hematology/Oncology at University of Oklahoma Health Sciences Center, while also receiving a Master's degree in Clinical and Translational Sciences. His work is focuses on gastrointestinal malignancies, with special focus on neuroendocrine tumors (NETs). His aim is to establish himself as an independent clinical investigator, with a focus on delivering novel therapeutics in NETs. His current research focuses on studying prognostic biomarkers in pancreatic NETs.

Publications

  • Published 6/20/2025

    Lazzaro A, Srinivasan M, Assi H. Cancer of Unknown Primary: A Case Report on the Recognition of Its Clinical Entity and Standard of Care Management. Cureus. 2025 Jun; 17(6):e86451. PMID: 40548152.

    Read at: PubMed

  • Published 8/2/2022

    Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surg Pathol Clin. 2022 Sep; 15(3):541-554. PMID: 36049835.

    Read at: PubMed

  • Published 7/1/2021

    Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021 07 01; 50(6):890-894. PMID: 34398071.

    Read at: PubMed

  • Published 10/1/2020

    Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020 10; 49(9):e95-e96. PMID: 33003100.

    Read at: PubMed

  • Published 6/25/2020

    Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA. 2020 Jun 25; 6(7):FSO581. PMID: 32802390.

    Read at: PubMed

View All 19 Publications:   View Full Profile in BUMC

Websites

Education

  • Amer Univ of Beirut, MD
  • University of Oklahoma, MS
  • Amer Univ of Beirut, BS

View all profiles